Alnylam Pharma Stock Outlook: Is ALNY Topping Out?
Alnylam Pharma Stock Outlook: For new entrants, chasing the momentum at this point would offer poor risk-reward dynamics. read more
Alnylam Pharma Stock Outlook: For new entrants, chasing the momentum at this point would offer poor risk-reward dynamics. read more
AMD’s stock surged 38% in last 3 months due to AI frenzy, outperforming S&P 500 and Nasdaq. Analysts predict 16.78% upside and $6.6B sales upside by 2027. read more
Latest Ratings for SG Date Firm Action From To Mar 2022 Oppenheimer Maintains Outperform Dec 2021 William Blair Initiates Coverage On Outperform Dec 2021 Morgan Stanley Initiates Coverage On Overweight View More Analyst Ratings for SG View the Latest Analyst Ratings read more
Latest Ratings for EMR Date Firm Action From To Mar 2022 Oppenheimer Upgrades Perform Outperform Feb 2022 Credit Suisse Maintains Outperform Feb 2022 Morgan Stanley Maintains Equal-Weight View More Analyst Ratings for EMR View the Latest Analyst Ratings read more
Latest Ratings for ADNT Date Firm Action From To Feb 2022 Wells Fargo Maintains Overweight Dec 2021 Barclays Downgrades Overweight Equal-Weight Nov 2021 Barclays Maintains Overweight View More Analyst Ratings for ADNT View the Latest Analyst Ratings read more
Latest Ratings for SAR Date Firm Action From To Jun 2021 Raymond James Initiates Coverage On Outperform Jun 2021 Oppenheimer Initiates Coverage On Outperform May 2020 Compass Point Maintains Buy View More Analyst Ratings for SAR View the Latest Analyst Ratings read more
NIO posts 17.5% June sales growth as Trump’s Tesla criticism fuels fresh EV policy debate. read more
UniFirst offers an annual dividend yield of 0.74% ($1.40 a year). Here’s how investors can earn $500 monthly. read more